Mecasermin: Difference between revisions
Content deleted Content added
m Added 1 doi to a journal cite using AWB (10388) |
No edit summary |
||
| Line 48: | Line 48: | ||
}} |
}} |
||
'''Mecasermin''' ([[International Nonproprietary Name|INN]] |
'''Mecasermin''' ([[International Nonproprietary Name|INN]]) (trade name '''Increlex''') is [[Recombinant DNA|recombinant]] human [[insulin-like growth factor 1]] (IGF-I), which is used for the long-term treatment of [[growth failure]] in children with severe primary IGF-I deficiency.<ref>{{cite journal|pmid=19707272|year=2009|last1=Fintini|first1=D|last2=Brufani|first2=C|last3=Cappa|first3=M|title=Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency|volume=5|issue=3|pages=553–9|pmc=2724186|journal=Therapeutics and clinical risk management|doi=10.2147/tcrm.s6178}}</ref><ref>{{cite web|url=http://www.drugs.com/increlex.html|title=Increlex|publisher=Drugs.com|accessdate=10 January 2010}}</ref> |
||
This drug is not to be confused with [[mecasermin rinfabate]] (trade name Iplex), which is a combination of recombinant human IGF-1 (rhIGF-1) and insulin-like growth factor binding protein-3 ([[IGFBP-3]]). IGFBP-3 serves to prolong the action of IGF-1 in the human body. |
This drug is not to be confused with [[mecasermin rinfabate]] (trade name Iplex), which is a combination of recombinant human IGF-1 (rhIGF-1) and insulin-like growth factor binding protein-3 ([[IGFBP-3]]). IGFBP-3 serves to prolong the action of IGF-1 in the human body. |
||
== |
==References== |
||
{{Reflist}} |
{{Reflist|2}} |
||
{{Pituitary and hypothalamic hormones and analogues}} |
|||
{{Peptidergics}} |
{{Peptidergics}} |
||
[[Category:Growth hormones]] |
[[Category:Growth hormones]] |
||
[[Category:Endocrinology]] |
[[Category:Endocrinology]] |
||
[[Category:Peptides]] |
|||
Revision as of 23:26, 12 June 2015
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Monograph |
| Routes of administration | Subcutaneous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C331H512N94O101S7 |
| Molar mass | 7648.67 g/mol g·mol−1 |
  (what is this?) (verify) | |
Mecasermin (INN) (trade name Increlex) is recombinant human insulin-like growth factor 1 (IGF-I), which is used for the long-term treatment of growth failure in children with severe primary IGF-I deficiency.[1][2]
This drug is not to be confused with mecasermin rinfabate (trade name Iplex), which is a combination of recombinant human IGF-1 (rhIGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3). IGFBP-3 serves to prolong the action of IGF-1 in the human body.
References
- ^ Fintini, D; Brufani, C; Cappa, M (2009). "Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency". Therapeutics and clinical risk management. 5 (3): 553–9. doi:10.2147/tcrm.s6178. PMC 2724186. PMID 19707272.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ "Increlex". Drugs.com. Retrieved 10 January 2010.
 | This hormonal preparation article is a stub. You can help Wikipedia by expanding it. |
